proadifen has been researched along with Cancer of Ovary in 1 studies
Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Proadifen (SKF-525A) is a P450 monooxygenase inhibitor with potential anti-proliferative activity and the ability to potentiate the toxicity of hypericin-mediated photodynamic therapy and mitoxantrone via alteration of ABC transport proteins." | 1.43 | Proadifen sensitizes resistant ovarian adenocarcinoma cells to cisplatin. ( Fedoročko, P; Hiľovská, L; Jendželovská, Z; Jendželovský, R; Kovaľ, J; Mikeš, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jendželovský, R | 1 |
| Jendželovská, Z | 1 |
| Hiľovská, L | 1 |
| Kovaľ, J | 1 |
| Mikeš, J | 1 |
| Fedoročko, P | 1 |
1 other study available for proadifen and Cancer of Ovary
| Article | Year |
|---|---|
Proadifen sensitizes resistant ovarian adenocarcinoma cells to cisplatin.
Topics: Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Carcinoma, Ovarian Epithelial; Cell Line, Tumo | 2016 |